EditorialEmerging Evidence Concerning Systemic Safety of Anti-VEGF Agents – Should Ophthalmologists Be Concerned?
References (17)
- et al.
Clinical update: new treatments for age-related macular degeneration
Lancet
(2007) - et al.
Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file
Am J Ophthalmol
(2011) - et al.
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy
Ophthalmology
(2006) - et al.
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Graefes Arch Clin Exp Ophthalmol
(2010) - et al.
Clinical practiceRetinal-vein occlusion
N Engl J Med
(2010) - et al.
Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity
N Engl J Med
(2011) - et al.
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
N Engl J Med
(2011) - et al.
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration
Arch Ophthalmol
(2010)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2011 Elsevier Inc. All rights reserved.